

<!-- EDGAR Online I-Metrix Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.12.8 -->
<!-- Round: 635da366-c089-495e-b76d-4eae6169f7a3 -->
<!-- Creation date: 2011-08-05T22:21:25Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2011-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:plx="http://www.protalix.com/20110630" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2011-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="plx-20110630.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE5673----1110-Q0003_STD_0_20110801_0" unitRef="shares" decimals="INF">85584310</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5673----1110-Q0003_STD_0_20100630_0" unitRef="iso4217_USD" decimals="-3">54961000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE5673----1110-Q0003_STD_0_20100630_0" unitRef="iso4217_USD_per_shares" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20100630_0" unitRef="iso4217_USD" decimals="-3">-1554000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE5673----1110-Q0003_STD_0_20100630_0" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20100630_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-124446000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE5673----1110-Q0003_STD_0_20100630_0_452905x444581" unitRef="shares" decimals="INF" id="fnid_24108038_3001_40000006">80881137</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20100630_0_452905x444581" unitRef="iso4217_USD" decimals="-3">81000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20100630_0_452905x453698" unitRef="iso4217_USD" decimals="-3">122811000</us-gaap:StockholdersEquity>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">1749000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">20282000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccountsPayableOtherCurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">8289000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">6146000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">4452000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">1720000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:Assets contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">71888000</us-gaap:Assets>
  <us-gaap:OtherReceivablesNetCurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">4884000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">1075000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">54052000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:InventoryNet contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">537000</us-gaap:InventoryNet>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">60309000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">51195000</us-gaap:AssetsCurrent>
  <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">1805000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">44054000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsPayableTradeCurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">5847000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD_per_shares" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:DeferredCosts contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">674000</us-gaap:DeferredCosts>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">71888000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">-8703000</us-gaap:StockholdersEquity>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">18944000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:Liabilities contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0" unitRef="iso4217_USD" decimals="-3">80591000</us-gaap:Liabilities>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-154189000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0_452905x444581" unitRef="shares" decimals="INF" id="fnid_24108038_7001_40000014">85581744</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0_452905x444581" unitRef="iso4217_USD" decimals="-3">86000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20110630_0_452905x453698" unitRef="iso4217_USD" decimals="-3">145400000</us-gaap:StockholdersEquity>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5673----1110-Q0003_STD_0_20091231_0" unitRef="iso4217_USD" decimals="-3">81266000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20091231_0" unitRef="iso4217_USD" decimals="-3">15883000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20091231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-106450000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE5673----1110-Q0003_STD_0_20091231_0_452905x444581" unitRef="shares" decimals="INF" id="fnid_24108038_1001_40000001">80841237</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20091231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">81000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20091231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">122252000</us-gaap:StockholdersEquity>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">942000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">18903000</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccountsPayableOtherCurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">8068000</us-gaap:AccountsPayableOtherCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">4563000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">7013000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:Assets contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">64729000</us-gaap:Assets>
  <us-gaap:OtherReceivablesNetCurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">2231000</us-gaap:OtherReceivablesNetCurrent>
  <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">942000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">55486000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:InventoryNet contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">1189000</us-gaap:InventoryNet>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" xsi:nil="true" />
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">57149000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">46333000</us-gaap:AssetsCurrent>
  <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">1663000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">35900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsPayableTradeCurrent contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">6272000</us-gaap:AccountsPayableTradeCurrent>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD_per_shares" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">64729000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">-11323000</us-gaap:StockholdersEquity>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">17454000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:Liabilities contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0" unitRef="iso4217_USD" decimals="-3">76052000</us-gaap:Liabilities>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-135448000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0_452905x444581" unitRef="shares" decimals="INF" id="fnid_24108038_5001_40000007">81248472</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0_452905x444581" unitRef="iso4217_USD" decimals="-3">81000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE5673----1110-Q0003_STD_0_20101231_0_452905x453698" unitRef="iso4217_USD" decimals="-3">124044000</us-gaap:StockholdersEquity>
  <us-gaap:GrossProfit contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">1460000</us-gaap:GrossProfit>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">532000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">27000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-5533000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">1703000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:Revenues contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">2282000</us-gaap:Revenues>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">4000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-20753000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ReimbursementRevenue contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">2479000</us-gaap:ReimbursementRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">532000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-1007000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">60000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-8000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-17996000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3" id="fnid_24108037_2_4">19325000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">27000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:CostOfRevenue contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:CostOfRevenue>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">5473000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-18270000</us-gaap:OperatingIncomeLoss>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">274000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-26305000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-46000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">271000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-2282000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3" id="fnid_24108037_2_7">2884000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">27000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD_per_shares" decimals="2">0.22</us-gaap:EarningsPerShareBasicAndDiluted>
  <plx:DepreciationAmortizationAndAssetImpairment contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">1455000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:SupplementalOfferingAndStockIssuanceCosts contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">5000</plx:SupplementalOfferingAndStockIssuanceCosts>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">712000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">16846000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="shares" decimals="0">80861857</plx:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <plx:OtherGainsLosses contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">-822000</plx:OtherGainsLosses>
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0" unitRef="iso4217_USD" decimals="-3">0</plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0_449149x447150" unitRef="iso4217_USD" decimals="-3">218000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0_449149x454085" unitRef="iso4217_USD" decimals="-3">314000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-17996000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0_452905x444581" unitRef="shares" decimals="INF" id="fnid_24108038_4001_40000004">39900</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0_452905x444581" unitRef="iso4217_USD" decimals="-3" id="fnid_24108038_4002_50000004">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0_452905x453698" unitRef="iso4217_USD" decimals="-3">532000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-Q0003_STD_181_20100630_0_452905x453698" unitRef="iso4217_USD" decimals="-3">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0">Q2</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0">PLX</dei:TradingSymbol>
  <dei:EntityRegistrantName contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0">PROTALIX BIOTHERAPEUTICS, INC.</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0">Accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0">2011</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0">2011-06-30</dei:DocumentPeriodEndDate>
  <dei:EntityCentralIndexKey contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0">0001006281</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:GrossProfit contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">472000</us-gaap:GrossProfit>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">521000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">259000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
NOTE 3 - STOCK TRANSACTIONS&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;
a.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
March 23,&amp;#xA0;2011, the Company issued and sold 4,000,000 shares
of Common Stock in an underwritten public offering at a price to
the public of $5.50 per share.&amp;#xA0;&amp;#xA0;The net proceeds to the
Company were approximately $20,590&amp;#xA0;(net of underwriting
commissions and issuance costs of $1,410).&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;
b.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During
the six months ended June 30, 2011, the Company issued a total of
333,272 shares of Common Stock in connection with the exercise of a
total of 333,272 options by certain employees and non-employees of
the Company.&amp;#xA0;&amp;#xA0;The Company received aggregate cash
proceeds equal to approximately $250 in connection with such
exercises.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
a.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
General&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 54pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
1.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Operation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Protalix
BioTherapeutics, Inc. and its wholly-owned subsidiary, Protalix
Ltd. (collectively, the &amp;#x201C;Company&amp;#x201D;), are
biopharmaceutical companies focused on the development and
commercialization of recombinant therapeutic proteins based on the
Company&amp;#x2019;s proprietary ProCellEx&lt;font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"&gt;tm&lt;/font&gt;
protein expression system (&amp;#x201C;ProCellEx&amp;#x201D;).&amp;#xA0;&amp;#xA0;In
September 2009, the Company formed another wholly-owned subsidiary
under the laws of the Netherlands in connection with the EMEA
application process in Europe.&amp;#xA0;&amp;#xA0;The Company&amp;#x2019;s
subsidiaries are referred to collectively herein as the
&amp;#x201C;Subsidiaries.&amp;#x201D;&amp;#xA0;&amp;#xA0;The Company&amp;#x2019;s lead
product development candidate is taliglucerase alfa for the
treatment of Gaucher disease which the Company is developing using
ProCellEx.&amp;#xA0;&amp;#xA0;In addition to taliglucerase alfa, the
Company is developing other certain products using
ProCellEx.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
September 2009, the Company successfully completed its phase III
pivotal trial of taliglucerase alfa.&amp;#xA0;&amp;#xA0;In July 2010, the
U.S. Food and Drug Administration (&amp;#x201C;FDA&amp;#x201D;) notified the
Company that it had accepted for review the Company&amp;#x2019;s new
drug application (NDA) for taliglucerase alfa for the treatment of
Gaucher disease and that it granted to taliglucerase alfa a
Prescription Drug User Fee Act (PDUFA) action date of February 25,
2011.&amp;#xA0;&amp;#xA0;On February&amp;#xA0;25, 2011, the FDA issued a
Complete Response Letter (a &amp;#x201C;CRL&amp;#x201D;) indicating that the
review is completed and questions remain that preclude the approval
of the NDA for taliglucerase alfa in its current
form.&amp;#xA0;&amp;#xA0;In August 2011, the Company submitted its reply to
the CRL.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;In
September 2009, the FDA&amp;#x2019;s Office of Orphan Product
Development granted &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;taliglucerase
alfa&lt;/font&gt; Orphan Drug Status.&amp;#xA0;&amp;#xA0;In addition to its
phase&amp;#xA0;III clinical trial, the Company initiated a clinical
study in December 2008 to evaluate the safety and efficacy of
switching Gaucher disease patients currently treated under the
current standard of care to treatment with &lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman"&gt;taliglucerase
alfa&lt;/font&gt;.&amp;#xA0;&amp;#xA0;In November 2010 the Company successfully
completed the nine month switchover trial in adults.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
November&amp;#xA0;30, 2009, Protalix Ltd. and Pfizer Inc.
(&amp;#x201C;Pfizer&amp;#x201D;) entered into an Exclusive License and Supply
Agreement (the &amp;#x201C;Pfizer Agreement&amp;#x201D;) pursuant to which
Protalix Ltd. granted Pfizer an exclusive, worldwide license to
develop and commercialize taliglucerase alfa, except in
Israel.&amp;#xA0;&amp;#xA0;Under the terms and conditions of the Pfizer
Agreement, Protalix Ltd. retained the right to commercialize
taliglucerase alfa in Israel.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
July 13, 2010, the French regulatory authority granted an
Autorisation Temporaire d&amp;#x2019;Utilisation (&amp;#x201C;ATU&amp;#x201D;), or
Temporary Authorization for Use, for taliglucerase alfa for the
treatment of Gaucher disease.&amp;#xA0;&amp;#xA0;The ATU allows Gaucher
disease patients in France to receive treatment with taliglucerase
alfa before marketing authorization for the product is granted in
the European Union.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;On
August 10, 2010, Pfizer entered into a $30 million short-term
supply agreement with the Ministry of Health of Brazil pursuant to
which the Company and Pfizer have provided taliglucerase alfa to
the Ministry of Health of Brazil for the treatment of Gaucher
disease patients.&amp;#xA0;&amp;#xA0;During the first quarter of 2011, the
Company and Pfizer supplied the remaining products deliverable
under the short-term supply agreement.&amp;#xA0;&amp;#xA0;During the second
quarter of 2011 Pfizer recorded an allowance for sales return in
connection with such agreement because the Ministry of Health of
Brazil requested that Pfizer consider the replacement of certain
vials that might expire during 2012.&amp;#xA0;&amp;#xA0;Revenue, net of
allowance for sales return, generated from the Ministry of Health
of Brazil was recorded by Pfizer and the Company recorded its
share, in accordance with the terms and conditions of the Pfizer
Agreement.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 54pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Liquidity and Financial Resources&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Successful
completion of the Company&amp;#x2019;s development programs and its
transition to operations is dependent upon obtaining necessary
regulatory approvals from the FDA prior to selling its products
within the United States, and foreign regulatory approvals must be
obtained to sell its products internationally.&amp;#xA0;&amp;#xA0;There can
be no assurance that the Company will receive regulatory approval
of any of its product candidates, and a substantial amount of time
may pass before the Company achieves a level of revenues adequate
to support its operations, if at all.&amp;#xA0;&amp;#xA0;The Company also
expects to incur substantial expenditures in connection with the
regulatory approval process for each of its product candidates
during the developmental period.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 72pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Based
on its current balance of cash and cash equivalents the Company
believes it should be able to maintain its current planned
development activities and the corresponding level of expenditures
for approximately the next 15 months, although no assurance can be
given that the Company will not need additional funds prior to such
time.&amp;#xA0;&amp;#xA0;The Company may need to seek additional financing
during the next 15 months&lt;font style="DISPLAY: inline; FONT-WEIGHT: bold"&gt;&amp;#xA0;&lt;/font&gt;if there are
unexpected increases expenses or other capital needs.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
b.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Basis of Presentation&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;The
accompanying unaudited condensed consolidated financial statements
of the Company have been prepared in accordance with accounting
principles generally accepted in the United States
(&amp;#x201C;GAAP&amp;#x201D;) for interim financial
information.&amp;#xA0;&amp;#xA0;Accordingly, they do not include all of the
information and notes required by GAAP for annual financial
statements.&amp;#xA0;&amp;#xA0;In the opinion of management, all
adjustments (of a normal recurring nature) considered necessary for
a fair statement of the results for the interim periods presented
have been included.&amp;#xA0;&amp;#xA0;Operating results for the interim
period are not necessarily indicative of the results that may be
expected for the full year.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;These
unaudited condensed consolidated financial statements should be
read in conjunction with the audited consolidated financial
statements in the Annual Report on Form 10-K for the year ended
December 31, 2010, filed by the Company with the Securities and
Exchange Commission.&amp;#xA0;&amp;#xA0;The comparative balance sheet at
December 31, 2010 has been derived from the audited financial
statements at that date.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
c.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Net loss per share&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Basic
and diluted loss per share (&amp;#x201C;LPS&amp;#x201D;) are computed by
dividing net loss by the weighted average number of shares of the
Company&amp;#x2019;s common stock, par value $.001 per share (the
&amp;#x201C;Common Stock&amp;#x201D;) outstanding for each
period.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 54pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Diluted
LPS does not include options of the Company in the amount of
7,604,195 and 7,537,094 shares of Common Stock for the six months
ended June 30, 2010 and 2011, respectively, and 7,930,824 and
7,435,271 shares of Common Stock for the three months ended June
30, 2010 and 2011, respectively, because the effect would be
anti-dilutive.&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
d.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
Reclassifications&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 54pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Certain
comparative figures have been reclassified to conform to the
current period presentation.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-4093000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-2049000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:Revenues contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">4892000</us-gaap:Revenues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">1410000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:PensionAndOtherPostretirementBenefitContributions contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">16000</us-gaap:PensionAndOtherPostretirementBenefitContributions>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-8811000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ReimbursementRevenue contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">3741000</us-gaap:ReimbursementRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">521000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">4770000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">77000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
NOTE 4 - SUBSEQUENT EVENTS&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 36pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During
July 2011, the Company issued a total of approximately 2,566 shares
of Common Stock in connection with the exercise of options to
purchase approximately 2,566 shares of Common Stock by certain
employees of the Company.&amp;#xA0;&amp;#xA0;The aggregate cash proceeds in
connection with the exercise of these options are equal to
$2.&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">250000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-18741000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="fnid_24108037_1_4">19331000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">73000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
  <us-gaap:CostOfRevenue contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">910000</us-gaap:CostOfRevenue>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">20590000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">4016000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-18906000</us-gaap:OperatingIncomeLoss>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">165000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0">&lt;div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
NOTE 2 - INVENTORIES&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"&gt;&amp;#xA0;&lt;/div&gt;
&lt;div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 36pt"&gt;&amp;#xA0;&lt;/td&gt;
&lt;td style="WIDTH: 18pt" align="right"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;
a.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td align="left"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;Inventory
as of June 30, 2011 and December 31, 2010 consisted of the
following:&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&amp;#xA0;&lt;/div&gt;
&lt;/div&gt;
&lt;div style="MARGIN-LEFT: 36pt" align="left"&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" cellspacing="0" cellpadding="0" width="85%"&gt;
&lt;tr&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="76%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
June&amp;#xA0;30,&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2011&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="10%" colspan="2" nowrap="nowrap"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
December&amp;#xA0;31,&lt;/font&gt;&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
2010&lt;/font&gt;&lt;/div&gt;
&lt;/div&gt;
&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"&gt;
&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="76%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Raw&amp;#xA0;materials&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;446&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td valign="bottom" width="1%" align="right"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;
$&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: right" valign="bottom" width="9%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;553&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="white"&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" valign="bottom" width="76%"&gt;
&lt;div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;Finished
goods&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;91&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 2px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;636&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr bgcolor="#CCFFCC"&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="76%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;537&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="PADDING-BOTTOM: 4px" valign="bottom" width="1%"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;1,189&lt;/font&gt;&lt;/td&gt;
&lt;td style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px" valign="bottom" width="1%" nowrap="nowrap"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="TEXT-INDENT: 0pt; DISPLAY: block"&gt;&lt;br /&gt;&lt;/div&gt;
&lt;div&gt;
&lt;table style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"&gt;
&lt;tr valign="top"&gt;
&lt;td style="WIDTH: 35.45pt"&gt;
&lt;div&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="WIDTH: 18pt"&gt;
&lt;div style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"&gt;
&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-WEIGHT: bold"&gt;
b.&lt;/font&gt;&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;td&gt;
&lt;div align="left"&gt;&lt;font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;During
the 6 months ended June 30, 2011, the Company recorded a $272
write-down of inventory under cost of revenues.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">8154000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">149000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:PensionAndOtherPostretirementBenefitExpense contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">77000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-652000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">149000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3" id="fnid_24108037_1_7">3788000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">20909000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD_per_shares" decimals="2">0.22</us-gaap:EarningsPerShareBasicAndDiluted>
  <plx:DepreciationAmortizationAndAssetImpairment contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">1801000</plx:DepreciationAmortizationAndAssetImpairment>
  <plx:SupplementalOfferingAndStockIssuanceCosts contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">60000</plx:SupplementalOfferingAndStockIssuanceCosts>
  <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">1995000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">15590000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="shares" decimals="0">83686094</plx:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <plx:OtherGainsLosses contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">-3510000</plx:OtherGainsLosses>
  <plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0" unitRef="iso4217_USD" decimals="-3">20650000</plx:ProceedsFromIssuanceOfCommonStockNetOfExpenses>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0_449149x447150" unitRef="iso4217_USD" decimals="-3">256000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0_449149x454085" unitRef="iso4217_USD" decimals="-3">265000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0_452905x440920" unitRef="iso4217_USD" decimals="-3">-18741000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0_452905x444581" unitRef="shares" decimals="INF" id="fnid_24108038_9001_40000012">333272</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0_452905x444581" unitRef="iso4217_USD" decimals="-3">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0_452905x444581" unitRef="iso4217_USD" decimals="-3">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0_452905x444581" unitRef="shares" decimals="INF" id="fnid_24108038_9001_40000009">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0_452905x453698" unitRef="iso4217_USD" decimals="-3">521000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0_452905x453698" unitRef="iso4217_USD" decimals="-3">249000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE5673----1110-Q0003_STD_181_20110630_0_452905x453698" unitRef="iso4217_USD" decimals="-3">20586000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:GrossProfit contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">613000</us-gaap:GrossProfit>
  <us-gaap:Revenues contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">1141000</us-gaap:Revenues>
  <us-gaap:ReimbursementRevenue contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">849000</us-gaap:ReimbursementRevenue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">-10041000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3" id="fnid_24108037_4_4">10347000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfRevenue contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">0</us-gaap:CostOfRevenue>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">-10150000</us-gaap:OperatingIncomeLoss>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">109000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3" id="fnid_24108037_4_7">1265000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0" unitRef="iso4217_USD_per_shares" decimals="2">0.12</us-gaap:EarningsPerShareBasicAndDiluted>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">9498000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0" unitRef="shares" decimals="0">80872940</plx:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <plx:OtherGainsLosses contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0" unitRef="iso4217_USD" decimals="-3">-528000</plx:OtherGainsLosses>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0_449149x447150" unitRef="iso4217_USD" decimals="-3">97000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5673----1110-Q0003_STD_91_20100630_0_449149x454085" unitRef="iso4217_USD" decimals="-3">151000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:GrossProfit contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">-4750000</us-gaap:GrossProfit>
  <us-gaap:Revenues contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">764000</us-gaap:Revenues>
  <us-gaap:ReimbursementRevenue contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">1449000</us-gaap:ReimbursementRevenue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">-13689000</us-gaap:NetIncomeLoss>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3" id="fnid_24108037_3_4">8768000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:CostOfRevenue contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">132000</us-gaap:CostOfRevenue>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">-13868000</us-gaap:OperatingIncomeLoss>
  <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">179000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3" id="fnid_24108037_3_7">1799000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0" unitRef="iso4217_USD_per_shares" decimals="2">0.16</us-gaap:EarningsPerShareBasicAndDiluted>
  <plx:ResearchDevelopmentAndEngineeringExpenseNet contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">7319000</plx:ResearchDevelopmentAndEngineeringExpenseNet>
  <plx:WeightedAverageNumberBasicDilutedSharesOutstanding contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0" unitRef="shares" decimals="0">85579534</plx:WeightedAverageNumberBasicDilutedSharesOutstanding>
  <plx:OtherGainsLosses contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0" unitRef="iso4217_USD" decimals="-3">-5382000</plx:OtherGainsLosses>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0_449149x447150" unitRef="iso4217_USD" decimals="-3">152000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5673----1110-Q0003_STD_91_20110630_0_449149x454085" unitRef="iso4217_USD" decimals="-3">127000</us-gaap:AllocatedShareBasedCompensationExpense>
  <context id="eol_PE5673----1110-Q0003_STD_91_20110630_0_449149x454085">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_91_20110630_0_449149x447150">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_91_20110630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2011-04-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_91_20100630_0_449149x454085">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-04-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_91_20100630_0_449149x447150">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-04-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_91_20100630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2010-04-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_181_20110630_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_181_20110630_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_181_20110630_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_181_20110630_0_449149x454085">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_181_20110630_0_449149x447150">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_181_20110630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_181_20100630_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_181_20100630_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_181_20100630_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_181_20100630_0_449149x454085">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_181_20100630_0_449149x447150">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ComponentOfOtherOperatingCostAndExpenseGeneralAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_181_20100630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20101231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20101231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20101231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20091231_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20091231_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20091231_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20091231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2009-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20110630_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20110630_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20110630_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20110630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2011-06-30</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20100630_0_452905x453698">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-06-30</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20100630_0_452905x444581">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-06-30</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20100630_0_452905x440920">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-06-30</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20100630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2010-06-30</instant>
    </period>
  </context>
  <context id="eol_PE5673----1110-Q0003_STD_0_20110801_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
    </entity>
    <period>
      <instant>2011-08-01</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <xbrll:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <xbrll:loc xlink:href="#fnid_24108037_1_4" xlink:label="fnid_24108037_1_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108037_1_7" xlink:label="fnid_24108037_1_7" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108037_2_4" xlink:label="fnid_24108037_2_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108037_2_7" xlink:label="fnid_24108037_2_7" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108037_3_4" xlink:label="fnid_24108037_3_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108037_3_7" xlink:label="fnid_24108037_3_7" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108037_4_4" xlink:label="fnid_24108037_4_4" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108037_4_7" xlink:label="fnid_24108037_4_7" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108038_1001_40000001" xlink:label="fnid_24108038_1001_40000001" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108038_3001_40000006" xlink:label="fnid_24108038_3001_40000006" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108038_4001_40000004" xlink:label="fnid_24108038_4001_40000004" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108038_4002_50000004" xlink:label="fnid_24108038_4002_50000004" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108038_5001_40000007" xlink:label="fnid_24108038_5001_40000007" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108038_7001_40000014" xlink:label="fnid_24108038_7001_40000014" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108038_9001_40000009" xlink:label="fnid_24108038_9001_40000009" xlink:type="locator"/>
    <xbrll:loc xlink:href="#fnid_24108038_9001_40000012" xlink:label="fnid_24108038_9001_40000012" xlink:type="locator"/>
    <xbrll:footnote xlink:label="footnote_24108044" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common Stock, $0.001 par value; Authorized - as of June 30, 2011, December 31, 2010 and June 30, 2010 - 150,000,000 shares.</xbrll:footnote>
    <xbrll:footnote xlink:label="footnote_24108045" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">*    Represents an amount less than $1.</xbrll:footnote>
    <xbrll:footnote xlink:label="footnote_24108046" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(1) Includes share-based compensation        256        218        152         97</xbrll:footnote>
    <xbrll:footnote xlink:label="footnote_24108047" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes share-based compensation        265        314        127        151</xbrll:footnote>
    <xbrll:footnoteArc xlink:from="fnid_24108037_1_4" xlink:to="footnote_24108046" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108037_1_7" xlink:to="footnote_24108047" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108037_2_4" xlink:to="footnote_24108046" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108037_2_7" xlink:to="footnote_24108047" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108037_3_4" xlink:to="footnote_24108046" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108037_3_7" xlink:to="footnote_24108047" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108037_4_4" xlink:to="footnote_24108046" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108037_4_7" xlink:to="footnote_24108047" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108038_1001_40000001" xlink:to="footnote_24108044" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108038_3001_40000006" xlink:to="footnote_24108044" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108038_4001_40000004" xlink:to="footnote_24108044" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108038_4002_50000004" xlink:to="footnote_24108045" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108038_5001_40000007" xlink:to="footnote_24108044" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108038_7001_40000014" xlink:to="footnote_24108044" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108038_9001_40000009" xlink:to="footnote_24108044" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
    <xbrll:footnoteArc xlink:from="fnid_24108038_9001_40000012" xlink:to="footnote_24108044" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:type="arc"/>
  </xbrll:footnoteLink>
</xbrl>